Accessibility Menu
AstraZeneca Plc logo

AstraZeneca Plc(NASDAQ) AZN

This security has been delisted. This page is retained for historical reference.

AstraZeneca Plc last closing stock price
MetricPriceDate
Last closeUSD 173.302026-07-29
AstraZeneca Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.1%USD 169.732026-07-22
1 month-9.24%USD 190.952026-06-29
3 month-7.51%USD 187.372026-04-30
Year to date-4.75%USD 181.952025-12-31
1 year+19.18%USD 145.412025-07-29
3 year+28.92%USD 134.422023-07-28
5 year+68.19%USD 103.042021-07-30
Since inception+5,109.88%USD 1.781993-05-12

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

AZN Financials

Key Financial Metrics (TTM)

Gross Margin

79.27%

Operating Margin

22.69%

Net Income Margin

17.02%

Return on Equity

21.68%

Return on Capital

17.54%

Return on Assets

8.96%

Earnings Yield

N/A

Dividend Yield

1.80%

Payout Ratio

47.05%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$48.56B

Operating Income

$13.88B

EBITDA

$20.49B

Operating Cash Flow

$13.81B

Capital Expenditure

-$5.07B

Free Cash Flow

$8.74B

Cash & ST Invst.

$4.96B

Total Debt

$32.20B

AstraZeneca Plc Performance Analysis

AstraZeneca Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 44,323,629,24617.2%
20232023-12-31USD 45,988,566,7143.8%
20242024-12-31USD 54,095,753,31017.6%
20252025-12-31USD 58,876,265,4478.8%
AstraZeneca Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-305.1%
Q42025-12-312.1%
Q12026-03-31-1.4%
Q22026-06-30-0.6%
AstraZeneca Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 1.052586.7%
20232023-12-31USD 1.9181.7%
20242024-12-31USD 2.2517.7%
20252025-12-31USD 3.2845.7%
AstraZeneca Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-303.2%
Q42025-12-31-8.6%
Q12026-03-3133.1%
Q22026-06-30-19.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$15.19B

+5.1%

Gross Profit

$11.18B

-6.7%

Gross Margin

73.55%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

96,100

N/A

Net Income

$2.48B

+1.1%

EBITDA

$4.98B

+0.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$4.96B

-30.2%

Total Debt

$32.20B

-1.9%

Accounts Receivable

$15.97B

+12.7%

Inventory

$6.92B

+7.1%

Long Term Debt

$25.97B

-0.0%

Short Term Debt

$6.23B

-9.1%

Return on Assets

8.96%

N/A

Return on Invested Capital

16.41%

N/A

Free Cash Flow

$2.13B

+45.9%

Operating Cash Flow

$2.89B

-14.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NVSNovartis AG
$158.83-0.64%
GSKGSK plc
$53.22-0.91%
RHHBYRoche Holding AG
$54.97-2.74%
BMYBristol-Myers Squibb Company
$63.10-0.79%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$19.63-0.20%
NOKNokia
$8.41-0.06%
SKHYSK Hynix
$126.79-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.